

Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy



“This represents a significant advance for regenerative medicine as the first product of its kind to receive approval to be studied in osteoarthritis of the knee - bringing novel commercial products to patients that are safe and effective at treating chronic illnesses”

Q&A with Arugula Sciences' CSO



Ramon Coronado, MS, PhD, Chief Scientific Officer, Arugula Sciences

Tell us about Arugula Sciences

Arugula Sciences is a clinical-stage biotech company with a clear mission of serving patients. We aim to bring novel cellular and biologic therapeutics to the clinic – this mission drives all our work.

What are some of these assets?

Our first clinical asset, human umbilical cord allograft (SIG001 or Signature Cord Prime™), is a product developed to help patients suffering from knee osteoarthritis.

What is your vision for Arugula Sciences, and how are you navigating the company towards a successful future?

We are very excited about becoming a leading biotech company in the field of regenerative medicine. This field of medicine needs a serious company leader to

demonstrate that some of these therapies have a place in the clinic and can provide transforming patient benefits.

[Arugula Sciences Launch](#)

[Full Q&A with Dr. Coronado](#)

Caris Life Sciences and ConcertAI Revolutionizing Healthcare



Caris Life Sciences, the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, announced a unique partnership to align the two companies' oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.

[Read full press release](#)

ReCode Therapeutics Announces Strategic Partnership & Development of mRNA Therapy



ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode's inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.

The CF Foundation will contribute up to \$15 million including an initial equity investment of \$10 million to support preclinical studies needed for an Investigational New Drug (IND) application and early clinical development of ReCode's CFTR mRNA therapy for CF. The investment includes a commitment by the CF Foundation to invest another \$5 million upon completion of milestones.

[Read full press release](#)

Salarius Pharmaceuticals Announces 2nd US Patent for Targeted Protein Degraders



Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisindoliny Acetamides and Methods of Treating Medical Disorders Using Same.”

The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037.

[Read full press release](#)

Baylor University Cyber Expertise Recognized and Ready to Protect



The National Security Agency (NSA) and Department of Homeland Security (DHS) have designated Baylor University as a National Center of Academic Excellence in Cyber Defense (CAE-CD), a program that addresses the critical shortage of professionals with cybersecurity skills and highlights the importance of higher education as a solution to defending America’s cyberspace.

Cybersecurity and data management have never been more important to life sciences companies. New data requirements in and outside of the United States continues to be an area of focus in the life sciences community and will be for years to come, particularly as pharma, biotech, and device companies, whether startups to multinationals, must grapple with the fast pace of change in the legal and regulatory requirements they face.

Congratulations we are proud to have Baylor expertise supporting our industry!

[Read full press release](#)

Texas Southern University Receives \$5.1M Grant for Cancer Research



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS



TEXAS SOUTHERN UNIVERSITY

CPRIT awarded Texas Southern University a \$5.1 million Core Facility Support Award in August 2018 to fund a state-of-the-art drug development core facility. The core facility award also allowed Texas Southern University to continue to strengthen and expand its unique capabilities to serve cancer investigators from Texas and across the nation.

It is noteworthy that the National Cancer Institute (NCI) selected Texas Southern University as a designated laboratory to provide contract services for cancer drug discovery and development in the nation. NCI selected a total of 18 organizations for 2022–2027 cycle to participate NCI Experimental Therapeutics (NExT) program. Texas Southern University is the only institution in Texas and the only HBCU participating in the NExT program among a group of elite institutions.

[Read full press release](#)

Call for Abstracts - 2023 MHSRS

Submission Deadline ends on February 19, 2023



Submit your abstracts to the The Military Health System Research Symposium (MHSRS) before February 19, 2023. Abstracts submitted to the MHSRS should represent original, unpublished work (not on-line, not in print). Abstracts can be submitted to MHSRS as well as to professional scientific society meetings. However, if the abstract is submitted to MHSRS and other military-related/DoD meetings and accepted, the submitter needs to decide which meeting to present at. Abstracts presented at other military-related or DoD meetings are ineligible for presentation at the MHSRS, unless there are extenuating circumstances.

[Apply now](#)

Medix Infusion Nets \$35M Series B Funding for Growth



Medix Infusion provides infusion and injectable therapy to chronically and acutely ill patients at home or in one of its many ambulatory infusion centers. Medix has closed a \$35 million Series B funding round led by Echo Health Ventures.

The company says it will use the funds to support organic growth and acquire the infusion operations of the Center for Neurology and Spine, a national leader in the treatment of neurological disorders that serves patients across five infusion suites in Arizona.

[Read full press release](#)

Cooley Continues Climb in US and Global M&A and Private Equity Rankings



With nearly \$40 billion in deal volume during the fourth quarter of 2022 and over \$176 billion in deal volume for the year, Cooley's M&A practice earned the firm top recognitions on the Bloomberg, Mergermarket and Refinitiv regional and global year-end M&A and

private equity league tables.

Cooley's world-class transactional team has worked on 1,600+ M&A deals for an aggregate value of more than \$760 billion since 2018 and has guided top companies and private equity sponsors in some of the market's largest and most complex transactions. The 180+ member M&A group spans 18 major business and technology centers in the US, Asia and Europe and represents all categories of participants in transactions.

[Read full press release](#)

Join BioNTX for Deep Dive into FDA Authorization and IND Applications

BIONTX

REGULATORY 201

Is your goal filing an IND?

Join Us!

Dallas

January 25


PEGASUS PARK

Fort Worth

January 26





Trey Putnam, PhD, RAC
Vice President,
Regulatory Affairs & Quality Assurance
Osteal Therapeutics

Join BioNTX for our Regulatory 201 educational breakfast meeting and hear from our guest speaker Dr. Trey Putnam at Osteal Therapeutics, learn what an Investigational New Drug (IND) Application is, how the IND process works, FDA's expectations for an IND and what to do when something goes wrong.

[Register now - Dallas](#)

[Register now - Fort Worth](#)

2023 Career EXPO - February 10th Meet PhD and Post Doc Candidates

BIONTX

Join BioNTX at our Career Expo on February 10th! Your company will have the opportunity to recruit and network with top local talent and provide them with information about your open positions, review their resumes, and create brand awareness.



**ARE YOU
HIRING?**

Join us at our Career Expo
on February 10, 2023

[Register now](#)

ARPA-H is Seeking Applications for Program Managers



ARPA-H is looking for Program Managers who will champion core and innovative ideas to improve health and health research. Texas Talent can stay here as many of these jobs are remote! ARPA-H accelerates better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems.

[Apply now](#)

BioNTX Seeking Business Development Professional



BioNTX is seeking a driven individual with strong sales and customer service skills. Review the job description below and apply if appropriate. Please feel free to pass this opportunity on to others!

[Job Description Details](#)

Upcoming Events & Opportunities in North Texas



Founders Academy Essentials
Capital Factory

Join Capital Factory to learn fundamental insights and tools to help dramatically



WISH Network Series
Health Wildcatters

Join Health Wildcatters at their Women in Science and Healthcare Series Event where they continue to gather, meet like-minded individuals, and learn more about the WISH

increase your odds of success in your startup.

January 17 - 19, 2023

[Learn more here](#)



**How to Optimize Your R&D
Tax Credits with ADP**

Biotechnology Innovation Organization

Join BIO to learn about eligible tax credit activities, where state R&D benefits may exist, and how to maximize the new ADP tax credit offering now available to BioNTX members.

January 24, 2023

[Learn more here](#)



LAUNCHBIO

MRL Ventures Fund
LaunchBio

Join LaunchBio and MRL Ventures to participate in a 1 minute pitch and a Q&A with investors, apply before **January 20, 2023** to be considered.

January 26, 2023

[Learn more here](#)



Meet MassChallenge Dallas
MassChallenge

Join MassChallenge to meet their team in Dallas and learn about the upcoming the 2023 US early stage program.

February 2, 2023

[Learn more here](#)

network.

January 23, 2023

[Learn more here](#)



Meeting with Texas Legislators
Healthcare Think Tank

Join Healthcare Think Tank to listen to Texas legislators discuss top healthcare issues for the 2023 Texas Legislative Session - including healthcare costs and potential reforms to the system, access to care, and public health.

January 25, 2023

[Learn more here](#)



TEXAS TECH UNIVERSITY
Innovation Hub
at Research Park

**Want to Accelerate Your Startup &
Win \$25,000?**
TTU Innovation Hub

Join the Texas Tech Innovation Hub for their seminar on how you can accelerate your startup and win \$25,000!

February 1, 2023

[Learn more here](#)

BioNTX works to build a strong bioscience and healthcare innovation community through collaborative peer to peer networking events and educational programming.

[Let us know about your event!](#)


[View the North Texas community calendar of events](#)

[Look at upcoming BioNTX events](#)



Join BioNTX

BioNTX delivers opportunities for Members to connect across the State. Join us and collaborate with others, receive industry insights and visibility. We serve as the voice and champion for the life science community in NTX.



<http://www.BioNTX.org> | 5000 Riverside Drive, Building 6, Suite 100E, Irving, TX 75039

[Unsubscribe kotto@biontx.org](#)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by kotto@biontx.org